IMMU-106

What IMMU-106 Means in Everyday Medical Language

IMMU-106 is a monoclonal antibody, which is a laboratory-made protein designed to target a specific protein called CD20. CD20 is found on the surface of B cells, a type of immune system cell, and on some lymphoma cells. By attaching to CD20, IMMU-106 helps the immune system recognize and attack these cancer cells. This action supports the body’s natural defenses in fighting certain lymphomas, which are cancers of the lymphatic system. IMMU-106 is also known by other names including Ha20, HCD20, and veltuzumab. These names refer to the same or very similar substances used in research and treatment.

Why IMMU-106 Can Matter in Cancer Care

IMMU-106 is important because it represents a way to help the immune system fight certain types of lymphoma. By targeting the CD20 protein on lymphoma cells, IMMU-106 can help the body’s immune system identify and destroy cancer cells. It is being studied as a treatment option for various lymphomas, though it may not yet be widely approved or used outside of clinical trials. Understanding IMMU-106 can help patients and caregivers follow discussions about treatment options and research developments.

What Patients Might See or Hear About IMMU-106

Patients might encounter the term IMMU-106 or its other names in medical reports, treatment plans, clinical trial information, or conversations with their care team. It may appear as part of a drug name or a treatment being considered or studied. Because IMMU-106 has several names, it can be confusing. Patients may also hear about it as a monoclonal antibody that targets CD20 to help kill lymphoma cells. Seeing any of these names does not automatically mean the same thing in every context.

Common Sources of Confusion and How to Avoid Them

IMMU-106 is known by multiple names—Ha20, HCD20, and veltuzumab—which can cause confusion. It’s important not to treat the term alone as a diagnosis or treatment recommendation. Instead, ask your care team what the term means in your specific medical report or treatment plan. This helps avoid misunderstandings about your care.

Practical Questions to Ask Your Care Team

If you see IMMU-106 or one of its other names in your medical records or hear it mentioned, the best step is to ask your care team how it applies to your situation. Questions you might ask include: What is IMMU-106? Is it part of my treatment plan or a clinical trial? How does it work? What are the possible benefits and risks? Understanding the context helps you make informed decisions and feel more confident about your care.

Safety and Next Steps

This information about IMMU-106 is educational and does not decide what is safe, appropriate, or effective for any individual patient. Treatments involving IMMU-106 may still be under study and not approved for all uses. Always rely on your care team’s advice about your diagnosis and treatment. If you have questions about IMMU-106 or related terms, bring them to your next appointment to get clear, personalized answers.